- Asimov and LOTTE BIOLOGICS have formed a strategic partnership to enhance cell line development and GMP manufacturing.
- The collaboration integrates Asimov’s CHO Edge platform with LOTTE BIOLOGICS’ manufacturing services, aiming to improve efficiency and reduce development timelines.
Asimov, a synthetic biology company focused on therapeutic design and manufacturing, and LOTTE BIOLOGICS, a global CDMO, have announced a strategic partnership to accelerate cell line development and scale-up to GMP manufacturing. The companies have already demonstrated successful process scale-up, laying the groundwork for efficient biopharmaceutical production.
The partnership integrates Asimov’s CHO Edge cell line development platform with LOTTE BIOLOGICS’ large-scale manufacturing capabilities. This combination is expected to streamline the transition from development to GMP production, reducing timelines for therapeutic developers.
Alec Nielsen, co-founder and CEO of Asimov, highlighted the benefits of this collaboration, stating, “We’re delighted to be directly integrating with LOTTE BIOLOGICS’ established manufacturing capabilities, meaning our customers can now transition seamlessly from cell line development to large-scale GMP production, and drastically shorten their development cycles.”
James Park, CEO of LOTTE BIOLOGICS, emphasised the broader industry impact, saying the partnership leverages both companies’ strengths to drive biopharmaceutical innovation. “Ultimately, our goal is to make a meaningful impact on patients’ lives, and we will continue striving to be a company that contributes to a healthier future for all,” he added.
This collaboration reinforces LOTTE BIOLOGICS’ position as a contract manufacturing leader while expanding Asimov’s role in advancing bioprocessing technology. The partnership aims to provide biopharmaceutical developers with a seamless pathway from cell line development to commercial-scale production.
Stay ahead of trends and best practices
